[1]
|
S. L. Cohn, “Surveillance, Epidemiology, and End Results (SEER) Database,” 2007, National Cancer Institute.
http://seer.cancer.gov
|
[2]
|
S. L. Cohn, A. D. J. Pearson, W. B. London, T. Monclair, P. F. Ambros, G. M. Brodeur, A. Faldum, B. Hero, T. Iehara, D. Machin, V. Mosseri, T. Simon, A. Garaventa, V. Castel and K. K. Matthay, “The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task force Report,” Journal of Clinical Oncology, Vol. 27, No. 2, 2009, pp. 289-297.
http://dx.doi.org/10.1200/ JCO.2008.16.6785
|
[3]
|
M. Kubota, M. Yagi, S. Kanada, N. Okuyama, Y. Kinoshita, S. Yamazaki, K. Asami, A. Ogawa and T. Watanabe, “Long-Term Follow-Up Status of Patients With Neuroblastoma after Undergoing Either Aggressive Surgery or Chemotherapy—A Single Institutional Study,” Journal of Pediatric Surgery, Vol. 39, No. 9, 2004, pp. 1328-1332.
http://dx.doi.org/10.1016/j.jpedsurg.2004.05.012
|
[4]
|
M. Kaneko, Y. Tsuchida, H. Muqishima, N. Ohnuma, K. Yamamoto, K. Kawa, M. Iwafuchi, T. Sawada and S. Suita, “Intensified Chemotherapy Increases the Survival Rates in Patients with Stage 4 Neuroblastoma with MYCN Amplification,” Journal of Pediatric Hematology/Oncology, Vol. 24, No. 8, 2002, pp. 613-621.
http://dx.doi.org/10.1097/00043426-200211000-00004
|
[5]
|
K. K. Matthay, C. P. Reynolds, R. C. Seeger, H. Shimada, E. S. Adkins, D. Haas-Kogan, R. B. Gerbing, W. B. London and J. G. Villablanca, “Long-Term Results for Children with High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children’s Oncology Group Study,” Journal of Clinical Oncology, Vol. 27, No. 7, 2009, pp. 1007-1013. http://dx.doi.org/10.1200/JCO.2007.13.8925
|
[6]
|
B. Kushner, K. Kramer, S. Modak and N. K. Cheung, “Anti-GD2 Monoclonal Antibody 3F8 Plus Granulocyte Macrophage Colony Stimulating Factor for Primary Refractory Neuroblastoma in Bone Marrow,” Proceedings of ASCO, Vol. 25, 2007, p. 9502.
|
[7]
|
K. W. Sung, M. H. Son, S. H. Lee, K. H. Yoo, H. H. Koo, J. Y. Kim, E. J. Cho, S. K. Lee, Y. S. Choi, D. H. Lim, J. S. Kim and D. W. Kim, “Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma: Results of SMC NB-2004 Study,” Bone Marrow Transplant, Vol. 48, No. 1, 2013, pp. 68-73. http://dx.doi.org/10.1038/bmt.2012.86
|
[8]
|
G. Surico, P. Muggeo, F. De Leonardis and N. Rigillo, “New Paclitaxel Cisplatin Based Chemotherapy Regimen for Advanced Stage, Recurrent, or Refractory Neuroblastoma—Preliminary Report,” Medical and Pediatric Oncology, Vol. 40, No. 2, 2003, pp. 130-132.
http://dx.doi.org/10.1002/mpo.10106
|
[9]
|
G. M. Brodeur, J. Pritchard, F. Berthold, N. L. Carlsen, V. Castel, R. P. Castelberry, B. De Bernardi, A. E. Evans, M. Favrot, F. Hedborg, et al., “Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and Response to Treatment,” Journal of Clinical Oncology, Vol. 11, 1993, pp. 1466-1477.
|
[10]
|
O. Burques, S. Navarro, R. Noquera, A. Pellín, A. Ruiz, V. Castel and A. Llombart-Bosch, “Prognostic Value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian Stroma-Poor) and Comparison with Other Prognostic Factors: A Study of 182 Cases from the Spanish Neuroblastoma Registry,” Virchows Archives, Vol. 449, No. 4, 2006, pp. 410-420.
http://dx.doi.org/10.1007/s00428-006-0253-y
|
[11]
|
Y. Hachitanda, M. Saito, I. Mori and M. Hamazaki, “Application of Fluorescent in Situ Hybridization to Detect N-myc Gene Amplification on Paraffin-Embedded Tissue Sections of Neuroblastoma,” Medical and Pediatric Oncology, Vol. 29, 1997, pp. 135-138.
|
[12]
|
G. M. Brodeur, M. D. Hogarty, Y. P. Mosse and J. M. Maris, “Neuroblastoma,” In: P. A. Pizzo, P. C. Adamson and D. G. Poplack, Eds., Principles and Practice of Pediatric Oncology. 6th Edition, Lippincott Williams and Wilkins, Philadelphia, 2011, pp. 886-922.
|
[13]
|
B. H. Kushner, R. J. O’Reilly, M. LaQuaglia and N. K. Cheung, “Dose-Intensive Use of Cyclophosphamide in Ablation of Neuroblastoma,” Cancer, Vol. 66, 1990, pp. 1095-1100.
http://dx.doi.org/10.1002/1097-0142(19900915)66:6<1095::AID-CNCR2820660603>3.0.CO;2-0
|
[14]
|
G. J. Veal, M. Cole, J. Errington, A. D. Pearson, A. B. Foot, G. Whyman and A. V. Boddy, “UKCCSG Pharmacology Working Group. Pharmacokinetics and Metabolism of 13-Cis-Retinoic Acid (Isotretinoin) in Children with High-Risk Neuroblastoma—A Study of the United Kingdom Children’s Cancer Study Group,” British Journal of Cancer, Vol. 96, No. 3, 2007, pp. 424-431.
http://dx.doi.org/10.1038/ sj.bjc.6603554
|
[15]
|
J. M. Maris, M. D. Hogarty, R. Baqatell and S. L. Cohn, “Neuroblastoma,” Lancet, Vol. 369, No. 9579, 2007, pp. 2106-2120.
http://dx.doi.org/10.1016/S0140-6736(07)60983-0
|
[16]
|
K. K. Matthay, J. G. Villablanca, R. C. Seeger, D. O. Stram, R. E. Harris, N. K. Ramsay, P. Swift, H. Shimada, C. T. Black, G. M. Brodeur, R. B. Gerbing and C. P. Reynolds, “Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. Children’s Cancer Group,” The New England Journal of Medicine, Vol. 341, 1999, pp. 1165-1173.
http://dx.doi.org/10.1056/NEJM199910143411601
|
[17]
|
M. Kaneko, Y. Tsuchida, J. Uchino, T. Takeda, M. Iwafuchi, N. Ohnuma, H. Mugishima, J. Yokoyama, H. Nishihira, K. Nakada, S. Sasaki, T. Sawada, K. Kawa, N. Nagahara, S. Suita and S. Sawaguchi, “Treatment Results of Advanced Neuroblastoma with the First Japanese Study Group Protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma,” Journal of Pediatric Hematology/Oncology, Vol. 21, No. 3, 1999, pp. 190-197.
http://dx.doi.org/10.1097/00043426-199905000-00006
|
[18]
|
C Tan, S. M. Sabai, A. S. Tin, T. C. Quah and L. Aung, “Neuroblastoma: Experience from National University Health System, Singapore (1987-2008),” Singapore Medical Journal, Vol. 53, 2012, pp. 19-25.
|
[19]
|
A. L. Yu, A. L. Gilman, M. F. Ozkaynak, W. B. London, S. G. Kreissman, H. X Chen, M. Smith, B. Anderson, J. G. Villablanca, K. K. Matthay, H. Shimada, S. A. Grupp, R. Seeger, C. P. Reynolds, A. Buxton, R. A. Reisfeld, S. D. Gillies, S. L. Cohn, J. M. Maris and P. M. Sondel, “Children’s Oncology Group. Anti-GD2 Antibody with GMCSF, Interleukin-2, and Isotretinoin for Neuroblastoma,” The New England Journal of Medicine, Vol. 363, No. 14, 2010, pp. 1324-1334.
http://dx.doi.org/10.1056/ NEJMoa0911123
|
[20]
|
R. C. Seeger, C. P. Reynolds, R. Gallego, D. O. Stram, R. B. Gerbing and K. K. Matthay, “Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children’s Cancer Group Study,” Journal of Clinical Oncology, Vol. 18, 2000, pp. 4067-4076.
|
[21]
|
E. M. Kiely, “Radical Surgery for Abdominal Neuroblastoma,” Seminars in Surgical Oncology, Vol. 9, No. 6, 1993, pp. 489-492.
http://dx.doi.org/10.1002/ssu.2980090606
|
[22]
|
D. von Schweinitz, B. Hero and F. Berthold, “The Impact of Surgical Radicality on Outcome in Childhood Neuroblastoma,” European Journal of Pediatric Surgery, Vol. 12, No. 6, 2002, pp. 402-409.
http://dx.doi.org/10.1055/s-2002-36952
|
[23]
|
M. P. La Quaglia, B. H. Kushner, W. Su, G. Heller, K. Kramer, S. Abramson, N. Rosen, S. Wolden and N. K. Cheung, “The Impact of Gross Total Resection on Local Control and Survival in High-Risk Neuroblastoma,” Journal of Pediatric Surgery, Vol. 39, No. 3, 2004, pp. 412-417. http://dx.doi.org/ 10.1016/j.jpedsurg.2003.11.028
|
[24]
|
A. L. Koivusalo, M. P. Pakarinen, R. J. Rintala and U. M. Saarinen-Pihkala, “Surgical Treatment of Neuroblastoma: Twenty-Three Years of Experience at a Single Institution,” Surgery Today, 2013, Epub Ahead of Print.
http://dx.doi.org/10.1007/s00595-013-0576-7
|
[25]
|
A. M. Davidoff, “Neuroblastoma,” Seminars in Pediatric Surgery, Vol. 21, No. 1, 2012, pp. 2-14.
http://dx.doi.org/10.1053/j.sempedsurg.2011.10.009
|
[26]
|
S. Mueller and K. K. Matthay, “Neuroblastoma: Biology and Staging,” Current Oncology Reports, Vol. 11, No. 6, 2009, pp. 431-438.
http://dx.doi.org/10.1007/s11912-009-0059-6
|